# The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

> **NCT04447183** · PHASE2 · UNKNOWN · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 120 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)
- **OTHER:** radioactive iodine

## Key facts

- **NCT ID:** NCT04447183
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-23
- **Primary completion:** 2024-08
- **Final completion:** 2024-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447183, "The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04447183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*